Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is still under investigation as adjuvant treatment for early-stage disease. Here, we performed a meta-analysis to evaluate the efficacy of adjuvant EGFR-TKI versus non-EGFR-TKI treatment in patients with comple...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ning, Wu, Zhuo-peng, Yang, Jie, Feng, Wei-neng, Yang, Sheng-li, Luo, Ying, Ye, Jun, Wang, Fei, Zhang, Xiao-wen, Xiao, Ye, Wu, Ling-ling, Gu, Wei-quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926719/
https://www.ncbi.nlm.nih.gov/pubmed/36782320
http://dx.doi.org/10.1186/s12957-023-02925-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926719/
https://www.ncbi.nlm.nih.gov/pubmed/36782320
http://dx.doi.org/10.1186/s12957-023-02925-x

Ejemplares similares